ArticleMediators of inflammation2026
REG3A: A Potential Fecal Biomarker for Ulcerative Colitis.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- REG3A: A Potential Fecal Biomarker for Ulcerative Colitis.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Regenerating islet-derived protein 3-alpha (REG3A), a member of the regenerating islet-derived protein (Reg) family, belongs to the C-type lectin class of antimicrobial peptides (AMPs). It has been recognized as a critical component of intestinal mucosal barrier damage and repair. In a prospective cohort (82 ulcerative colitis [UC] patients, 20 controls), UC patients were stratified by clinical partial Mayo Score (pMS) and endoscopic activity. Fecal REG3A levels were measured across distinct patient cohorts, and diagnostic performance was evaluated and compared against fecal calprotectin (FC) and a combined model using receiver operating characteristic (ROC) analysis. REG3A expression was also evaluated in intestinal biopsies via immunohistochemistry. Fecal REG3A levels increased stepwise with UC clinical severity (p < 0.001), peaking in the severe activity group. A combined model of REG3A and FC outperformed either biomarker alone in differentiating disease activity, achieving the highest area under the curves (AUCs) for distinguishing remission from mild activity and mild from moderate activity. Immunohistochemistry confirmed REG3A expression in active UC colonic tissues. Our results indicate that fecal REG3A serves as a promising biomarker for assessing disease activity in UC. Its combination with FC enhances the accuracy of predicting clinical severity in UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.